Please assess the completion status of the following clinical trial:

Trial Title: Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years old.~* Histologic proof of melanoma reviewed and confirmed by MSKCC.~* A confirmed EBRAFV600E or KBRAFV600K mutation.~* Stage IV melanoma, or advanced stage III not curable by surgery. Patients with active CNS metastases will be allowed on the study.~* Measurable disease by RECIST v1.1.~* ECOG performance status 3 or 4. The basis for the grading of performance is strict; there must be clear justification of the performance status grade (e.g. patient is confined to bed \> 50% of time, or cannot carry out ADLs, or is otherwise disabled by burden of disease such as requiring supplemental O2).~* Patients must be able to swallow pills~* Adequate hematologic, hepatic and renal function as defined by the following:~* Absolute Neutrophil Count ≥ 1.0 x 109/L~* Hemoglobin ≥8.0g/dL, occasional transfusions are acceptable as vemurafenib does not have significant hematologic toxicities.~* Total bilirubin ≤2.0x the upper limit of normal, ≤3.0x the upper limit of normal if the patient has Gilbert's Syndrome.~* Alkaline phosphatase ≤2.0x the upper limit of normal.~* AST and ALT ≤2.0x the upper limit of normal.~* Serum creatinine ≤ 1.5x the upper limit of normal.~Exclusion Criteria:~* Uveal melanoma as primary.~* Concurrent chemotherapy, immunotherapy, or radiotherapy.~* Prior treatment with a RAF inhibitor. Other prior chemotherapy, immunotherapy, or radiotherapy will be allowed including prior treatment with a MEK inhibitor Patients must have had complete recovery from any adverse events or toxicities of prior cancer-directed therapies.~* Pregnant or lactating women.~* A second active malignancy. Prior malignancy will be allowed as long as the patient is known to be free of disease for at least 2 years. Patients with indolent B-cell malignancies will not be eligible.~* QTc interval \> 500 msec.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vemurafenib (Type: EXPERIMENTAL): This is a single institution phase II trial in stage III or IV melanoma patients with poor ECOG performance status (3 or 4). Patients must have melanoma with a BRAFV600E or BRAFV600K or mutation with measurable disease not curable by surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).